Data from: Alpha-defensin binding expands human adenovirus tropism
Data files
Jul 24, 2024 version files 139.96 MB
-
2024_AdVTropismDefensin_Fig01A_platemap.pdf
134.53 KB
-
2024_AdVTropismDefensin_Fig01A_Rep01_platescan.tif
548.80 KB
-
2024_AdVTropismDefensin_Fig01A_Rep02_platescan.tif
537.58 KB
-
2024_AdVTropismDefensin_Fig01B_analysis.prism
31.50 KB
-
2024_AdVTropismDefensin_Fig01B_platemap.pdf
128.48 KB
-
2024_AdVTropismDefensin_Fig01B_quantitation.xlsx
15.24 KB
-
2024_AdVTropismDefensin_Fig01B_Rep01_platescan.tif
728.52 KB
-
2024_AdVTropismDefensin_Fig01B_Rep02_platescan.tif
741.41 KB
-
2024_AdVTropismDefensin_Fig01B_Rep03_platescan.tif
686.72 KB
-
2024_AdVTropismDefensin_Fig01C_analysis.prism
30.95 KB
-
2024_AdVTropismDefensin_Fig01C_platemap.pdf
127.82 KB
-
2024_AdVTropismDefensin_Fig01C_quantitation.xlsx
18.79 KB
-
2024_AdVTropismDefensin_Fig01C_Rep01_platescan.tif
562.65 KB
-
2024_AdVTropismDefensin_Fig01C_Rep02_platescan.tif
674.01 KB
-
2024_AdVTropismDefensin_Fig01C_Rep03_platescan.tif
678.80 KB
-
2024_AdVTropismDefensin_Fig02B_amplicon_sgRNA.RTF
47.71 KB
-
2024_AdVTropismDefensin_Fig02B_R1_001.fastq.gz
2.05 MB
-
2024_AdVTropismDefensin_Fig02B_R2_001.fastq.gz
2.17 MB
-
2024_AdVTropismDefensin_Fig02C_Rep01_flowcytometry.acs
1.07 MB
-
2024_AdVTropismDefensin_Fig02C_Rep02_flowcytometry.acs
1.12 MB
-
2024_AdVTropismDefensin_Fig02C_Rep03_flowcytometry.acs
1.02 MB
-
2024_AdVTropismDefensin_Fig02C_samplename.xlsx
17.31 KB
-
2024_AdVTropismDefensin_Fig02D_platemap.pdf
229.64 KB
-
2024_AdVTropismDefensin_Fig02D_platescan.tif
1.05 MB
-
2024_AdVTropismDefensin_Fig02E_analysis.prism
38.21 KB
-
2024_AdVTropismDefensin_Fig02E_quantitation.xlsx
21.44 KB
-
2024_AdVTropismDefensin_Fig02E_Rep01_flowcytometry.acs
5.95 MB
-
2024_AdVTropismDefensin_Fig02E_Rep02_flowcytometry.acs
9.33 MB
-
2024_AdVTropismDefensin_Fig02E_Rep03_flowcytometry.acs
8.26 MB
-
2024_AdVTropismDefensin_Fig03A_Rep01_CARKO_platemap.pdf
125.21 KB
-
2024_AdVTropismDefensin_Fig03A_Rep01_CARKO_well_platescan.tif
1.03 MB
-
2024_AdVTropismDefensin_Fig03A_Rep01_control_well_platemap.pdf
45.42 KB
-
2024_AdVTropismDefensin_Fig03A_Rep01_control_well_platescan.tif
219.29 KB
-
2024_AdVTropismDefensin_Fig03A_Rep02_and_03_platemap.pdf
297.15 KB
-
2024_AdVTropismDefensin_Fig03A_Rep02_platescan.tif
2.72 MB
-
2024_AdVTropismDefensin_Fig03A_Rep03_platescan.tif
3.14 MB
-
2024_AdVTropismDefensin_Fig03A_Rep04_05_platemap.pdf
296.09 KB
-
2024_AdVTropismDefensin_Fig03A_Rep04_platescan.tif
2.81 MB
-
2024_AdVTropismDefensin_Fig03A_Rep05_platescan.tif
2.91 MB
-
2024_AdVTropismDefensin_Fig03B_bottom_analysis.prism
187.75 KB
-
2024_AdVTropismDefensin_Fig03B_bottom_quantitation.xlsx
18.66 KB
-
2024_AdVTropismDefensin_Fig03B_top_analysis.prism
156.07 KB
-
2024_AdVTropismDefensin_Fig03B_top_quantitation.xlsx
18.95 KB
-
2024_AdVTropismDefensin_Fig04A_analysis.prism
44.26 KB
-
2024_AdVTropismDefensin_Fig04A_quantitation.xlsx
21.96 KB
-
2024_AdVTropismDefensin_Fig04A_Rep01_flowcytometry.acs
8.57 MB
-
2024_AdVTropismDefensin_Fig04A_Rep02_flowcytometry.acs
8.92 MB
-
2024_AdVTropismDefensin_Fig04A_Rep03_flowcytometry.acs
7.15 MB
-
2024_AdVTropismDefensin_Fig04B_Rep01_03_platemap.pdf
334.72 KB
-
2024_AdVTropismDefensin_Fig04B_Rep01_platescan.tif
3.24 MB
-
2024_AdVTropismDefensin_Fig04B_Rep02_platescan.tif
3.32 MB
-
2024_AdVTropismDefensin_Fig04B_Rep03_platescan.tif
3.73 MB
-
2024_AdVTropismDefensin_Fig04B_Rep04_platemap.pdf
298.04 KB
-
2024_AdVTropismDefensin_Fig04B_Rep04_platescan.tif
2.82 MB
-
2024_AdVTropismDefensin_Fig04C_analysis.prism
157.86 KB
-
2024_AdVTropismDefensin_Fig04C_quantitation.xlsx
20.97 KB
-
2024_AdVTropismDefensin_Fig04D_analysis.prism
137.15 KB
-
2024_AdVTropismDefensin_Fig04D_quantitation.xlsx
19.41 KB
-
2024_AdVTropismDefensin_Fig05A_Rep01_07_platemap.pdf
296.96 KB
-
2024_AdVTropismDefensin_Fig05A_Rep01_platescan.tif
2.77 MB
-
2024_AdVTropismDefensin_Fig05A_Rep02_platescan.tif
2.82 MB
-
2024_AdVTropismDefensin_Fig05A_Rep03_platescan.tif
2.90 MB
-
2024_AdVTropismDefensin_Fig05A_Rep04_platescan.tif
2.71 MB
-
2024_AdVTropismDefensin_Fig05A_Rep05_platescan.tif
3.21 MB
-
2024_AdVTropismDefensin_Fig05A_Rep06_platescan.tif
3.16 MB
-
2024_AdVTropismDefensin_Fig05A_Rep07_platescan.tif
2.77 MB
-
2024_AdVTropismDefensin_Fig05A_Rep08_09_platemap.pdf
291.63 KB
-
2024_AdVTropismDefensin_Fig05A_Rep08_platescan.tif
2.75 MB
-
2024_AdVTropismDefensin_Fig05A_Rep09_platescan.tif
2.94 MB
-
2024_AdVTropismDefensin_Fig05B_bottom_analysis.prism
196.64 KB
-
2024_AdVTropismDefensin_Fig05B_bottom_quantitation.xlsx
24.59 KB
-
2024_AdVTropismDefensin_Fig05B_top_analysis.prism
153.69 KB
-
2024_AdVTropismDefensin_Fig05B_top_quantitation.xlsx
22.82 KB
-
2024_AdVTropismDefensin_Fig06B_analysis.prism
138.47 KB
-
2024_AdVTropismDefensin_Fig06B_platemap.pdf
34.99 KB
-
2024_AdVTropismDefensin_Fig06B_quantitation.xlsx
21.42 KB
-
2024_AdVTropismDefensin_Fig06B_Rep01_Ad35_platescan.tif
371.10 KB
-
2024_AdVTropismDefensin_Fig06B_Rep01_Ad37_platescan.tif
358.16 KB
-
2024_AdVTropismDefensin_Fig06B_Rep02_Ad35_platescan.tif
380.46 KB
-
2024_AdVTropismDefensin_Fig06B_Rep02_Ad37_platescan.tif
337.45 KB
-
2024_AdVTropismDefensin_Fig06B_Rep03_Ad35_platescan.tif
324.10 KB
-
2024_AdVTropismDefensin_Fig06B_Rep03_Ad37_platescan.tif
302.82 KB
-
2024_AdVTropismDefensin_Fig06B_Rep04_Ad35_platescan.tif
335.98 KB
-
2024_AdVTropismDefensin_Fig06B_Rep04_VH_platescan.tif
320.17 KB
-
2024_AdVTropismDefensin_Fig06B_Rep05_Ad35_platescan.tif
323.75 KB
-
2024_AdVTropismDefensin_Fig06B_Rep05_Ad37_platescan.tif
335.73 KB
-
2024_AdVTropismDefensin_Fig06B_Rep05_VH_platescan.tif
332.01 KB
-
2024_AdVTropismDefensin_Fig06B_Rep06_Ad35_platescan.tif
315.73 KB
-
2024_AdVTropismDefensin_Fig06B_Rep06_VH_platescan.tif
346.96 KB
-
2024_AdVTropismDefensin_Fig06B_Rep07_Ad35_platescan.tif
345.07 KB
-
2024_AdVTropismDefensin_Fig06B_Rep07_VH_platescan.tif
339.49 KB
-
2024_AdVTropismDefensin_Fig06C_analysis.prism
34.08 KB
-
2024_AdVTropismDefensin_Fig06C_quantitation.xlsx
19.03 KB
-
2024_AdVTropismDefensin_Fig06D_Rep01_platemap.pdf
220.85 KB
-
2024_AdVTropismDefensin_Fig06D_Rep01_platescan.tif
587.60 KB
-
2024_AdVTropismDefensin_Fig06D_Rep02_and_03_platemap.pdf
250.98 KB
-
2024_AdVTropismDefensin_Fig06D_Rep02_and_03_platescan.tif
632.08 KB
-
2024_AdVTropismDefensin_Fig07_quantitation.xlsx
20.18 KB
-
2024_AdVTropismDefensin_Fig07_Rep01_flowcytometry.acs
5.49 MB
-
2024_AdVTropismDefensin_Fig07_Rep02_flowcytometry.acs
4.61 MB
-
2024_AdVTropismDefensin_Fig07_Rep03_flowcytometry.acs
4.93 MB
-
2024_AdVTropismDefensin_Fig07A_D_analysis.prism
74.63 KB
-
README.md
9.74 KB
Abstract
Mammalian α-defensins are a family of abundant effector peptides of the mucosal innate immune system. Although primarily considered to be antimicrobial, α-defensins can increase rather than block infection by certain prominent bacterial and viral pathogens in cell culture and in vivo. We have shown previously that exposure of mouse and human adenoviruses (HAdVs) to α-defensins is able to overcome competitive inhibitors that block cell binding, leading us to hypothesize a defensin-mediated binding mechanism that is independent of known viral receptors. To test this hypothesis, we used genetic approaches to demonstrate that none of several primary receptors nor integrin co-receptors are needed for human α-defensin-mediated binding of HAdV to cells; however, infection remains integrin dependent. Thus, our studies have revealed a novel pathway for HAdV binding to cells that bypasses viral primary receptors. We speculate that this pathway functions in parallel with receptor-mediated entry and contributes to α-defensin-enhanced infection of susceptible cells. Remarkably, we also found that in the presence of α-defensins, HAdV tropism is expanded to non-susceptible cells, even when viruses are exposed to a mixture of both susceptible and non-susceptible cells. Therefore, we propose that in the presence of sufficient concentrations of α-defensins, such as in the lung or gut, integrin expression rather than primary receptor expression will dictate HAdV tropism in vivo. In summary, α-defensins may contribute to tissue tropism not only through the neutralization of susceptible viruses but also by allowing certain defensin-resistant viruses to bind to cells independently of previously described mechanisms.
https://doi.org/10.5061/dryad.d2547d89h
Description of the data and file structure
Files are provided for each figure as follows:
Figure 1A:
Scans of 96-well plates of A549 cells infected with green fluorescent protein-expressing viruses were obtained using a multi-mode plate scanner (*_platescan.tif) from 2 independent replicates (Rep##). Experimental variables include human defensin 5 (HD5) and two human adenovirus (HAdV) serotypes, C5 and D64. Samples were arranged as indicated on the plate map (.pdf).
Figure 1B:
Scans of 96-well plates of A549 cells infected with green fluorescent protein-expressing viruses were obtained using a multi-mode plate scanner (*_platescan.tif) from 3 independent replicates (Rep##). Samples were arranged as indicated on the plate map (.pdf). Experimental variables include wheat germ agglutinin (WGA) and human defensin 5 (HD5). From these images, total well fluorescence was enumerated using Fiji (.xlsx) by applying a rolling ball background subtraction and measuring integrated density limited to the threshold indicated in the .xlsx file. Sample wells were normalized to control wells (no WGA, no HD5), and the normalized data from all replicates was analyzed using GraphPad Prism 10.0.2 (.prism).
Figure 1C:
Scans of 96-well plates of A549 cells infected with green fluorescent protein-expressing viruses were obtained using a multi-mode plate scanner (*_platescan.tif files) from 3 independent replicates (Rep##). Samples were arranged as indicated on the plate map (.pdf). Experimental variables include neuraminidase (NA) and human defensin 5 (HD5). From these images, total well fluorescence was enumerated using Fiji (.xlsx) by applying a rolling ball background subtraction and measuring integrated density limited to the threshold indicated in the .xlsx file. Sample wells were normalized to control wells (no NA, no HD5), and the normalized data from all replicates was analyzed using GraphPad Prism 10.0.2 (.prism).
Figure 2B:
Paired end reads were obtained from an Illumina platform (.fastq.gz) for an amplicon from the coxsackievirus and adenovirus receptor (CAR) knockout clone used in this study. Amplicon and sgRNA sequences (.rtf) are provided.
Figure 2C:
Archival cytometry standard (.ACS) files containing flow cytometry data and FlowJo 10.7.1 analysis is provided for 3 independent replicates (Rep##). A table (.xlsx) of the tube number in the ACS files corresponding to each sample is provided. Experimental variables include antibody (anti-CAR vs isotype) and A549 cell genotype: wild type (WT) or CAR knockout (KO).
Figure 2D:
A scan of a 96-well plate of cells infected with a 3-fold dilution series (top to bottom) of green fluorescent protein-expressing viruses was obtained using a multi-mode plate scanner (*_platescan.tif). Experimental variables include two human adenovirus (HAdV) serotypes, C5 and B35, and A549 cell genotype: wild type (WT) or CAR knockout (KO). Samples were arranged as indicated on the plate map (.pdf).
Figure 2E:
Archival cytometry standard (.ACS) files containing flow cytometry data and FlowJo 10.7.1 analysis is provided for 3 independent replicates (Rep##). A table (.xlxs) of the tube number in the ACS files corresponding to each sample and analysis to calculate fold change in geometric mean fluorescence (GMF) is provided. This data was analyzed using GraphPad Prism 10.0.2 (.prism). Experimental variables include human defensin 5 (HD5), two human adenovirus (HAdV) serotypes (C5/D64-HVR1 and C5/D64-HVR1/RGE), and A549 cell genotype: wild type (WT) or CAR knockout (KO). Red values in columns C, J, and Q of the .xlxs table correspond to the geometric mean fluorescence of control samples (without HD5) that were used as the denominator to calculate fold change for other samples.
Figure 3A:
Scans of 96-well plates of A549 cells infected with green fluorescent protein-expressing viruses were obtained using a multi-mode plate scanner (*_platescan.tif files) from 5 independent replicates (Rep##). Samples were arranged as indicated on the corresponding plate maps (.pdf).
Figure 3B:
Analysis of the images in Figure 3A. From these images, total well fluorescence was enumerated using Fiji (.xlsx) by measuring integrated density limited to the threshold indicated in the .xlsx file. Experimental variables include human defensin 5 (HD5) and three human adenovirus (HAdV) serotypes (C5, C5/D64-HVR1, and C5/D64-HVR1/RGE). Data for WT A549 cells (*top) and CAR knockout A549 cells (*bottom) were both normalized to WT A549 cells infected in the absence of HD5 for each virus. The normalized data from all replicates was analyzed using GraphPad Prism 10.0.2 (.prism).
Figure 4A:
Archival cytometry standard (.ACS) files containing flow cytometry data and FlowJo 10.7.1 analysis is provided for 3 independent replicates (Rep##). A table (.xlxs) of the tube number in the ACS files corresponding to each sample and analysis to calculate fold change in geometric mean fluorescence (GMF) is provided. This data was analyzed using GraphPad Prism 10.0.2 (.prism). Experimental variables include the E21 methyl mutant of human defensin 5 (E21me HD5), two human adenovirus (HAdV) serotypes (C5/D64-HVR1 and C5/D64-HVR1/RGE), and A549 cell genotype: wild type (WT) or CAR knockout (KO). Red values in columns C, J, and Q of the .xlxs table correspond to the geometric mean fluorescence of control samples (without E21me HD5) that were used as the denominator to calculate fold change for other samples.
Figure 4B:
Scans of 96-well plates of A549 cells infected with green fluorescent protein-expressing viruses were obtained using a multi-mode plate scanner (*_platescan.tif files) from 4 independent replicates (Rep##). Samples were arranged as indicated on the corresponding plate maps (.pdf).
Figure 4C and 4D:
Analysis of the images in Figure 4B. From these images, total well fluorescence was enumerated using Fiji (.xlsx) by measuring integrated density limited to the threshold indicated in the .xlsx file. Experimental variables include the E21 methyl mutant of human defensin 5 (E21me HD5), three human adenovirus (HAdV) serotypes (C5, C5/D64-HVR1, and C5/D64-HVR1/RGE), and A549 cell genotype: wild type (WT) or CAR knockout (KO). Data for WT A549 cells (Figure 4C) and CAR knockout A549 cells (Figure 4D) were both normalized to WT A549 cells infected in the absence of HD5 for each virus. The normalized data from all replicates was analyzed using GraphPad Prism 10.0.2 (.prism).
Figure 5A:
Scans of 96-well plates of A549 cells infected with green fluorescent protein-expressing viruses were obtained using a multi-mode plate scanner (*_platescan.tif files) from 9 independent replicates (Rep##). Samples were arranged as indicated on the corresponding plate maps (.pdf).
Figure 5B:
Analysis of the images in Figure 4B. From these images, total well fluorescence was enumerated using Fiji (.xlsx) by measuring integrated density limited to the threshold indicated in the .xlsx file. Experimental variables include the E21 methyl mutant of human defensin 5 (E21me HD5), three human adenovirus (HAdV) serotypes (C5, C5/D64-HVR1, and C5/D64-HVR1/RGE), and A549 cell genotype: wild type (WT) or CAR knockout (KO). Data for WT A549 cells (*top) and CAR knockout A549 cells (*bottom) were both normalized to WT A549 cells infected in the absence of HD5 for each virus. The normalized data from all replicates was analyzed using GraphPad Prism 10.0.2 (.prism).
Figure 6B:
Scans of 96-well plates of A549 cells infected with green fluorescent protein-expressing viruses were obtained using a multi-mode plate scanner (*_platescan.tif) from multiple independent replicates (Rep##). Samples were arranged as indicated on the plate map (.pdf). Experimental variables include human defensin 5 (HD5) and human adenovirus (HAdV) serotype: HAdV-B35 (Ad35), HAdV-D37 (Ad37), and HAdV-B35/D37 Vertex/HVR1 (VH). Viruses studied in parallel have the same replicate number. From these images, total well fluorescence was enumerated using Fiji (.xlsx) by applying a rolling ball background subtraction and measuring integrated density limited to the threshold indicated in the .xlsx file. Sample wells were normalized to control wells (no HD5), and the normalized data from all replicates was analyzed using GraphPad Prism 10.0.2 (.prism).
Figure 6C:
Analysis of the images in Figure 6D. From these images, total well fluorescence was enumerated using Fiji (.xlsx) by measuring integrated density limited to the threshold indicated in the .xlsx file. Experimental variables include human defensin 5 (HD5) and HAP1 cell genotype: wild type (WT) or CD46 knockout (KO). Data for CD46 KO cells was normalized to WT HAP1 cells infected in the absence of HD5 for each virus. The normalized data from all replicates was analyzed using GraphPad Prism 10.0.2 (.prism).
Figure 6D:
Scans of 96-well plates of HAP1 cells infected with green fluorescent protein-expressing viruses were obtained using a multi-mode plate scanner (*_platescan.tif) from multiple independent replicates (Rep##). Samples were arranged as indicated on the plate map (.pdf).
Figure 7:
Archival cytometry standard (.ACS) files containing flow cytometry data and FlowJo 10.7.1 analysis is provided for 3 independent replicates (Rep##). A table (.xlxs) of the tube number in the ACS files corresponding to each sample and analysis to calculate %GFP positive is provided. This data was analyzed using GraphPad Prism 10.0.2 (.prism). Experimental variables include human defensin 5 (HD5), cell type (A549 and CTM-93), and culture format (monoculture or mixed).
